MiMedx (MDXG) 10-Q 8 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 25, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'MIMEDX GROUP, INC.	'
Entity Central Index Key	'0001376339	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	97,851,013
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$6,061,756	$6,754,485
Accounts receivable, net	13,706,524	7,653,561
Inventory, net	4,533,062	3,022,784
Prepaid expenses and other current assets	1,544,369	657,961
Total current assets	25,845,711	18,088,791
Property and equipment, net of accumulated depreciation of $2,694,005 and $2,279,840, respectively	3,761,633	1,071,625
Goodwill	4,040,443	4,040,443
Intangible assets, net of accumulated amortization of $5,638,565 and $4,848,756, respectively	11,648,506	11,911,749
Deposits and other long term assets	0	70,000
Total assets	45,296,293	35,182,608
Current liabilities:	'	'
Accounts payable	2,205,778	1,251,684
Accrued compensation	4,560,380	2,753,237
Accrued expenses	1,410,159	990,697
Other current liabilities	155,077	75,154
Total current liabilities	8,331,394	5,070,772
Earn-out liability payable in MiMedx common stock	0	5,792,330
Convertible Senior Secured Promissory Notes, net	0	4,012,442
Other liabilities	1,426,469	299,762
Total liabilities	9,757,863	15,175,306
Commitments and contingencies	0	0
Stockholders' equity:	'	'
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $.001 par value; 130,000,000 shares authorized; 97,686,013 issued and 97,636,013 outstanding for 2013 and 88,423,169 issued and 88,373,169 outstanding for 2012	97,686	88,423
Additional paid-in capital	107,834,381	89,627,601
Treasury stock (50,000 shares at cost)	-25,000	-25,000
Accumulated deficit	-72,368,637	-69,683,722
Total stockholders' equity	35,538,430	20,007,302
Total liabilities and stockholders' equity	$45,296,293	$35,182,608

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
ASSETS	'	'
Property and equipment, net of accumulated depreciation	$2,694,005	$2,279,840
Intangible assets, net of accumulated amortization	$5,638,565	$4,848,756
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	130,000,000	130,000,000
Common stock, shares issued (in shares)	97,686,013	88,423,169
Common stock, shares outstanding (in shares)	97,636,013	88,373,169
Treasury stock, shares (in shares)	50,000	50,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Net sales	$16,115,708	$7,954,046	$41,186,943	$16,544,110
Cost of sales	2,113,438	1,425,336	6,216,940	3,499,117
Gross margin	14,002,270	6,528,710	34,970,003	13,044,993
Operating expenses:	'	'	'	'
Research and development expenses	1,287,361	838,690	3,458,585	1,748,847
Selling, general and administrative expenses	12,711,225	5,756,559	31,948,607	11,443,611
Impairment of intangible assets	0	1,798,495	0	1,798,495
Fair value adjustment of earn-out liability	0	1,320,000	0	1,320,000
Amortization of intangible assets	259,575	449,692	789,809	1,117,646
Operating income (loss)	-255,891	-3,634,726	-1,226,998	-4,383,606
Other income (expense), net	'	'	'	'
Amortization of debt discount	0	-439,064	-1,328,439	-1,222,290
Interest expense, net	-4,527	-145,582	-32,503	-451,196
Income (loss) before income tax provision	-260,418	-4,219,372	-2,587,940	-6,057,092
Income tax provision	-46,700	0	-96,975	0
Net Income (loss)	($307,118)	($4,219,372)	($2,684,915)	($6,057,092)
Net income (loss) per common share - basic and diluted (in dollars per share)	$0	($0.05)	($0.03)	($0.07)
Weighted average shares outstanding - basic and diluted (in shares)	96,914,856	84,493,164	95,429,988	84,091,014

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) (USD $)	Total	Convertible Preferred Stock Series A [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$20,007,302	$0	$88,423	$89,627,601	($25,000)	($69,683,722)
Balance (in shares) at Dec. 31, 2012	'	0	88,423,169	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Share-based compensation expense	4,155,005	0	'	4,155,005	0	0
Exercise of stock options	1,516,580	0	1,610	1,514,970	0	0
Exercise of stock options (in shares)	1,610,426	0	1,610,426	'	'	'
Exercise of warrants	1,480,124	0	1,206	1,478,918	0	0
Exercise of warrants (in shares)	'	0	1,205,499	'	'	'
Common stock issued for 5% convertible note	5,272,004	0	5,272	5,266,732	0	0
Common stock issued for 5% convertible note (in shares)	5,272,004	0	5,272,004	'	'	'
Common stock issued for earn-out liability	5,792,330	0	1,175	5,791,155	0	0
Common stock issued for earn-out liability (in shares)	1,174,915	0	1,174,915	'	'	'
Net income (loss)	-2,684,915	0	0	0	0	-2,684,915
Balance at Sep. 30, 2013	$35,538,430	$0	$97,686	$107,834,381	($25,000)	($72,368,637)
Balance (in shares) at Sep. 30, 2013	'	0	97,686,013	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) (Parenthetical)	Sep. 30, 2013
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'
Convertible note percentage (in hundredths)	5.00%

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net income (loss)	($2,684,915)	($6,057,092)
Adjustments to reconcile net income (loss) to net cash from operating activities:	'	'
Depreciation	414,165	354,425
Loss on fixed asset disposal	8,359	0
Amortization of intangible assets	789,809	1,117,646
Impairment of intangible assets	0	1,798,495
Amortization of debt discount and deferred financing costs	1,328,439	1,222,290
Share-based compensation	4,155,005	1,755,669
Change in fair value of earn-out liability	0	1,320,000
Increase (decrease) in cash resulting from changes in:	'	'
Accounts receivable	-6,052,963	-4,278,205
Inventory	-1,510,278	-1,089,733
Prepaid expenses	-913,644	-382,051
Other assets	70,000	19,213
Accounts payable	954,094	-39,139
Accrued compensation	1,807,143	1,393,016
Accrued expenses	419,462	92,986
Accrued interest	-41,641	312,775
Other liabilities	132,302	-1,408
Net cash flows from operating activities	-1,124,663	-2,461,113
Cash flows from investing activities:	'	'
Purchases of equipment	-2,008,407	-401,864
Patent application costs	-526,566	0
Net cash flows from investing activities	-2,534,973	-401,864
Cash flows from financing activities:	'	'
Proceeds from exercise of warrants	1,480,124	5,925,539
Proceeds from exercise of stock options	1,516,580	885,034
Repayment of convertible debt related to acquisition	0	-427,126
Principal payments of equipment leases	-29,797	-11,002
Repurchase of warrants	0	-568
Net cash flows from financing activities	2,966,907	6,371,877
Net change in cash	-692,729	3,508,900
Cash and cash equivalents, beginning of period	6,754,485	4,112,326
Cash and cash equivalents, end of period	$6,061,756	$7,621,226

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the nine months ended September 30, 2013 and 2012, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2012, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
	You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2012, included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2013.
	The Company operates in one business segment, Biomaterials, which includes the design, manufacture, and marketing of products and amnion tissue processing for a variety of surgical applications using the Company’s proprietary biomaterials—CollaFix™, HydroFix®, EpiFix® and AmnioFix®.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant accounting policies	'
	Significant Accounting Policies
	Please see Note 2 to our Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2012, for a description of all significant accounting policies.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Accounts Receivable
	Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
	The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.  The Company has $115,000 and $49,000 in the allowance for doubtful accounts as of September 30, 2013, and December 31, 2012, respectively.  Actual customer collections could differ from estimates.  The approximate provision during the nine months ended September 30, 2013 and September 30, 2012, was $99,000 and 119,000, respectively, and there were approximately $33,000 and $23,000 of write-offs for the nine months ended September 30, 2013 and September 30, 2012, respectively.
	Inventories
	Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
	Revenue Recognition
	The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with the field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  The Company recorded approximately $178,000 and $88,000 for net sales returns provisions for the three months ended September 30, 2013 and 2012, respectively, and there were approximately $153,000 and $135,000 of charges against the related reserve during the three months ended September 30, 2013 and 2012, respectively. The Company recorded approximately $648,000 and $233,000 for net sales returns provisions for the nine months ended September 30, 2013 and 2012, respectively, and there were approximately $485,000 and $161,000 of charges against the related reserve during the nine months ended September 30, 2013 and 2012, respectively.
	Patent Costs
	The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $527,000 of patent costs during the first nine months of 2013. There were not any patent costs capitalized for the nine months ended September 30, 2012.
	Recent Accounting Pronouncements
	The Company considers the applicability and impact of all ASUs. For the nine months ended September 30, 2013, and through the date of this report, all ASUs issued, effective and not yet effective, were assessed and determined to be either not applicable or are expected to have minimal impact on our financial position or results of operations.

Liquidity_and_Managements_Plan

Liquidity and Management's Plans	9 Months Ended
	Sep. 30, 2013
Liquidity and management's plans [Abstract]	'
Liquidity and management's plans	'
	Liquidity and Management’s Plans
	As of September 30, 2013, the Company had approximately $6,062,000 of cash and cash equivalents.  The Company reported total current assets of approximately $25,846,000 and current liabilities of approximately $8,331,000 as of September 30, 2013.  The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consisted of the following items as of September 30, 2013, and December 31, 2012:
		September 30, 2013			December 31, 2012
	Raw materials	$	206,962		$	233,747
	Work in process	3,276,557			1,598,537
	Finished goods	1,422,275			1,349,121
		4,905,794			3,181,405
	Reserve for obsolescence	(372,732		)	(158,621		)
	Inventory, net	$	4,533,062		$	3,022,784

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and equipment	'
	Property and Equipment
	Property and equipment consist of the following as of September 30, 2013, and December 31, 2012:
		30-Sep-13			31-Dec-12
	Leasehold improvements	$	2,638,508		$	1,022,230
	Lab and clean room equipment	2,265,203			1,887,645
	Furniture and office equipment	954,797			431,563
	Construction in progress	597,130			10,027
		6,455,638			3,351,465
	Less accumulated depreciation	(2,694,005		)	(2,279,840		)
		$	3,761,633		$	1,071,625
	Included in property and equipment is approximately $176,000 of capital leases. The corresponding liability is included in other liabilities in the accompanying condensed consolidated balance sheet. Also included is approximately $1.0 million in leasehold improvements paid for by the landlord of our new facility with a corresponding liability included in long term liabilities which is amortized over the term of the lease.

Intangible_Assets_and_Royalty_

Intangible Assets and Royalty Agreement	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible assets and royalty agreement	'
	Intangible Assets and Royalty Agreement
	Intangible assets activity is summarized as follows:
		30-Sep-13								31-Dec-12
		Weighted	Gross		Accumulated			Net		Gross		Impairment			Accumulated			Net
		Average	Carrying		Amortization			Carrying		Carrying		Adjustment			Amortization			Carrying
		Amortization	Value					Value		Value								Value
		Lives
	Intangible assets subject to amortization:
	License-Shriners Hsp for Children & USF Research (a)	10 years	$	996,000	$	(662,333	)	$	333,667	$	996,000	$	—		$	(587,633	)	$	408,367
	License - SaluMedica LLC Spine Repair (b)	10 years	1,547,324		(1,547,324		)	—		2,399,000		(851,676		)	(1,547,324		)	—
	License - Polyvinyl Alcohol Cryogel (c)	10 years	1,720,181		(1,319,956		)	400,225		2,667,000		(946,819		)	(1,223,561		)	496,620
	Customer Relationships (d)	14 years	3,520,000		(691,429		)	2,828,571		3,520,000		—			(502,857		)	3,017,143
	Supplier Relationships (d)	14 years	241,000		(47,339		)	193,661		241,000		—			(34,428		)	206,572
	Patents & Know-How (d)	17 years	5,614,177		(1,088,267		)	4,525,910		5,530,000		—			(790,000		)	4,740,000
	Micronized Processing Know-How (d)	14 years	2,160,000		(270,000		)	1,890,000		2,160,000		—			(154,286		)	2,005,714
	Licenses/Permits (d)	3 years	13,000		(11,917		)	1,083		13,000		—			(8,667		)	4,333
			15,811,682		(5,638,565		)	10,173,117		17,526,000		(1,798,495		)	(4,848,756		)	10,878,749
	Intangible assets not subject to amortization:
	Trade Names/Trademarks (d)	indefinite	1,008,000		—			1,008,000		1,008,000		—			—			1,008,000
	In-process Research & Development-Other (d)	indefinite	25,000		—			25,000		25,000		—			—			25,000
	Patents in Process (e)	indefinite	442,389					442,389		—		—			—			—
			$	16,844,682	$	(5,638,565	)	$	11,648,506	$	18,559,000	$	(1,798,495	)	$	(4,848,756	)	$	11,911,749
	(a)	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.  The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date).  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products.
	(b)	License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair.  This license was acquired through the acquisition of SpineMedica Corp.  In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value.
	(c)	On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol hydrogel.  The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date).  The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales.  On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement.  As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000.  In September 2012, the cost of the license was deemed to be impaired and reduced to its fair value.  At September 30, 2013, and December 31, 2012, there are no additional amounts accrued for this obligation due to its contingent nature.
	(d)	On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.
	(e)	Capitalized external legal and other registration costs in connection with internally developed tissue based patents that are pending issuance. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
	Future Amortization Expense
	Expected future amortization of intangible assets is as follows:
		Estimated Amortization Expense
	Year ending  December 31,
	2013 (a)	$	263,833
	2014	1,050,998
	2015	1,028,944
	2016	981,950
	2017	891,753
	Thereafter	5,955,639
		$	10,173,117
	(a)	Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after September 30, 2013.

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-Term Debt
	The following table summarizes our long-term debt:
		September 30,		December 31,
		2013		2012
	$5M Convertible Senior Secured Promissory Notes including interest at 5% per annum payable quarterly through December 31, 2013, and an additional one time 5% interest charge payable on January 15, 2013 if not repaid by December 31, 2012, collateralized by a first priority lien shared equally with holder of the Convertible Line of Credit with Related Party in all of the patents and intellectual property owned by the Company subordinated to the Convertible Debt related to acquisition for Surgical Biologics intellectual property until repaid. (a)	$	—	$	5,313,645
	Total debt	—		5,313,645
	Less unamortized debt discount	—		(1,301,203		)
	Less current portion	—		—
	Long-term portion	$	—	$	4,012,442
	(a) Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. On December 31, 2011, a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company's share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052, which was recorded as a debt discount and was amortized to interest expense using the effective interest rate over the life of the note.
	Senior Secured Promissory Notes
	From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000.  The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO.  In total, the principal of the Notes is convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note.
	As of December 31, 2012, the Company had not repaid the Notes in full and as a result the Company was required to pay each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender’s Notes as of December 31, 2012.  The additional interest was accrued on a monthly basis during the year.
	In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share.  The warrants expire in 5 years.  The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique.  The total direct costs of approximately $47,800 were recorded as deferred financing costs and were amortized over the term of the Notes using the effective interest method.  Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.
	During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock.  The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000.  In conjunction with this exchange, approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation.  Included in this total are 532,260 shares representing the Chief Executive Officer’s conversion of his Note.  This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the nine months ended September 30, 2013.
	Line of Credit
	On May 17, 2013, the Company and Bank of America, N.A. (the “Lender”) entered into a Loan Agreement (the “Loan Agreement”).  The Loan Agreement provides the Company with a secured revolving line of credit (the “Revolving Line of Credit”) of up to $3,000,000, and includes a sub-limit of up to $1,000,000 for the issuance of letters of credit.  The Revolving Line of Credit is secured by the Company's accounts receivable and inventory.  The Company intends to utilize the Revolving Line of Credit for general corporate purposes. As of the date of this filing, the Company has not made any draws under the Revolving Line of Credit.
	Accrued interest with respect to principal amounts outstanding under the Loan Agreement is payable in arrears on a monthly basis calculated at the rate of LIBOR plus two percent (2%). The principal amount outstanding under the Loan Agreement and any accrued and unpaid interest is due no later than May 1, 2014, and the Revolving Line of Credit is subject to certain prepayment penalties upon early termination of the Revolving Line of Credit.   The Loan Agreement is subject to renewal by the Lender at the end of the term.
	The Loan Agreement contains covenants that limit under certain circumstances the ability of the Company to, among other things, merge with or acquire other entities, incur new liens, incur additional indebtedness, sell assets outside of the ordinary course of business, make loans, advances or other extensions of credit or engage in any business activities substantially different from the Company's present business without the Lender's consent. The Loan Agreement also requires the Company to maintain certain financial covenants, including a minimum funded debt to adjusted EBITDA ratio and a minimum fixed charge coverage ratio. The Company is in compliance with these covenants.

Net_Income_loss_Per_Share

Net Income (loss) Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Income (loss) Per Share	'
	Net Income (loss) Per Share
	Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method.  For all periods presented, diluted net loss per share is the same as basic net loss per share, as the inclusion of equivalent shares from outstanding common stock options, warrants and convertible debt would be anti-dilutive.
	The following table sets forth the computation of basic and diluted net loss per share:
		Three months ended							Nine months ended
		September 30,							September 30,
		2013				2012			2013			2012
	Net income (loss)	$	(307,118	)		$	(4,219,372	)	$	(2,684,915	)	$	(6,057,092	)
	Denominator for basic earnings per share - weighted average shares	96,914,856				84,493,164			95,429,988			84,091,014
	Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	—				—			—			—
	Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	96,914,856				84,493,164			95,429,988			84,091,014
	Income (loss) per common share - basic and diluted	$	—			$	(0.05	)	$	(0.03	)	$	(0.07	)
	(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:
		Nine months ended September 30,
		2013			2012
	Outstanding Stock Options	15,139,543			12,642,833
	Outstanding Warrants	1,923,669			3,241,668
	Convertible Debt, promissory notes	—			5,313,133
	Convertible Line of Credit with Related Party	—			1,391,524
		17,063,212			22,589,158

Equity

Equity	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Equity	'
	Equity
	Stock Incentive Plans
	The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at September 30, 2013, totaled 375,000.  On March 6, 2013, the Board of Directors approved 6,000,000 additional shares to be made available under the 2006 Plan, bringing the maximum number of shares of common stock which can be issued under the 2006 Plan to 22,500,000 at September 30, 2013. The shareholders approved the increase on May 9, 2013.
	Activity with respect to the stock options is summarized as follows:
		Number of		Weighted-				Weighted-		Aggregate
		Shares		Average				Average		Intrinsic
				Exercise				Remaining		Value
				Price				Contractual
								Term
								(in years)
	Outstanding at January 1, 2013	13,614,135		$	1.42
	Granted	3,368,000		5.19
	Exercised	(1,610,426	)	0.94
	Unvested options forfeited	(179,167	)	3.82
	Vested options expired	(52,999	)	1.11
	Outstanding at September 30, 2013	15,139,543		2.28				7.9		$	31,918,608
	Vested at September 30, 2013	6,482,824		1.25				6.6		$	18,911,451
	Vested or expected to vest at September 30, 2013 (a)	14,824,937		$	2.25			7.9		$	31,649,823
	(a)	Includes forfeiture adjusted unvested shares.
	The intrinsic value of the options exercised during the nine months ended September 30, 2013, was approximately $7,182,000.
	Following is a summary of stock options outstanding and exercisable at September 30, 2013:
		Options Outstanding								Options Exercisable
	Range of Exercise Prices	Number outstanding		Weighted-		Weighted-				Number Exercisable		Weighted-
				Average		Average						Average
				Remaining		Exercise						Exercise Price
				Contractual		Price
				Term
				(in years)
	$0.50 - $0.76	1,340,935		3.9		$	0.65			1,340,935		$	0.65
	$0.87 - $1.35	6,656,908		7.9		1.2				3,336,870		1.19
	$1.40 - $2.29	1,686,700		6.4		1.62				1,436,698		1.65
	$2.33 - $3.75	2,159,500		9		2.75				368,321		2.52
	$3.95 - $6.02	3,035,000		9.5		5.07				—		—
	$6.11 - $6.75	260,500		9.7		6.49				—		—
		15,139,543		7.9		$	2.28			6,482,824		$	1.25
	Total unrecognized compensation expense related to granted stock options at September 30, 2013, was approximately $11,438,000 and is expected to be recognized over a weighted-average period of 2.2 years.
	The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
	The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
		Nine months ended September 30,
		2013		2012
	Expected volatility	61.41 - 64.56%		45.75 - 64.3%
	Expected life (in years)	6		6
	Expected dividend yield	—		—
	Risk-free interest rate	0.85 -1.88%		0.62 - 1.62%
	The weighted-average grant date fair value for options granted during the nine months ended September 30, 2013 was approximately $3.00.
	During the first nine months of 2013, the Company granted 419,300 shares of restricted stock with a weighted-average grant date fair value of $5.58 which vest over a 1 to 3 year period.  As of September 30, 2013, there was approximately $1,894,000 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.5 years.
	For the three and nine months ended September 30, 2013 and 2012, the Company recognized stock-based compensation as follows:
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013			2012				2013			2012
	Cost of sales	$	75,287		$	11,643			$	198,119		$	65,132
	Research and development	110,694			70,754				309,461			217,885
	Selling, general and administrative	1,481,785			587,072				3,647,425			1,472,652
		$	1,667,766		$	669,469			$	4,155,005		$	1,755,669
	Warrants
	The Company grants common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long term equity capital to the Company and as additional compensation to consultants and advisors.  The warrants are granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances.  The warrants have been issued for terms of five years.
	Following is a summary of the warrant activity for the nine months ended September 30, 2013:
		Number of		Weighted-
		Warrants		Average
				Exercise
				Price per
				Warrant
	Warrants outstanding at January 1, 2013	3,129,168		$	1.04
Warrants exercised:
Contingent warrants related to private placement of common stock	(62,500	)	0.01
Callable warrants	(266,666	)	1.5
Other	(876,333	)	1.23
Warrants outstanding at September 30, 2013	1,923,669		$	0.93
Warrants may be exercised in whole or in part by:
•	notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or
•	election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.
These warrants are not mandatorily redeemable, and do not obligate the Company to repurchase its equity shares by transferring assets or issuing a variable number of shares.
The warrants require that the Company deliver shares as part of a physical settlement or a net-share settlement, at the option of the holder, and do not provide for a net-cash settlement.
All of our warrants are classified as equity as of September 30, 2013, and December 31, 2012.

Income_taxes

Income taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income taxes	'
	Income taxes
	The Company has incurred net losses since its inception, and therefore, no current income tax liabilities have been incurred for the periods presented.  However, the Company does have tax obligations in certain states.  This expense and related liability is included in the accompanying financial statements as income tax provision and accounts payable, respectively.  The amount of federal operating loss carryforwards was approximately $43,400,000 at September 30, 2013.  A valuation allowance is recorded to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that a portion or none of the deferred tax assets will be realized.  After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management has determined that a full valuation allowance is necessary as of September 30, 2013.  Additionally, the Company has various tax credit carryforwards of approximately $1,400,000 as of September 30, 2013.

Supplemental_disclosure_of_cas

Supplemental disclosure of cash flow and non-cash investing and financing activities	9 Months Ended
	Sep. 30, 2013
Supplemental Cash Flow Elements [Abstract]	'
Supplemental disclosure of cash flow and non-cash investing and financing activities	'
		Supplemental disclosure of cash flow and non-cash investing and financing activities:
	Selected cash payments, receipts, and noncash activities are as follows:
		Nine Months Ended
		September 30,
		2013		2012
	Cash paid for interest	$	22,971	$	8,738
	Income taxes paid	96,967		—
	Purchases of property, plant and equipment financed capital leases	107,259		83,016
	Stock issuance of 167,086 shares in lieu of Director's fees	—		184,653
	Beneficial conversion related to line of credit with related party	—		514,456
	Stock issuance in connection with Earn-Out Liability of 1,174, 915 shares for 2013 and
	2,632,576 shares for 2012	5,792,330		3,185,223
	Stock issuance of 5,272,004 shares in exchange for convertible debt	5,272,004		—
	Company issued shares of 167,183 for cashless exercise	—		167
	Stock issuance of 893,267 shares in payment of Convertible Secured Promissory Notes	—		893,267
	related to acquisition of Surgical Biologics
	Tenant improvement incentive	996,866		—

Contractual_Commitments

Contractual Commitments	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contractual Commitments	'
	Contractual Commitments and Contingencies
	Contractual Commitments
	In addition to the Capital Leases noted under Property and Equipment above, the Company has entered into operating lease agreements for facility space and equipment.  The estimated annual lease payments are as follows:
	12-month period ended September 30
	2014	$	784,771
	2015	1,251,301
	2016	1,329,436
	2017	1,369,696
	2018	1,410,754
	Thereafter	478,326
		$	6,624,284
	Letters of Credit
	As a condition of the leases for the Company's facility space we are obligated under standby letters of credit in the amount of approximately $525,000. These obligations decrease in value at various times over the lives of the leases.
	FDA Untitled Letter
	Initially, MiMedx processed its tissue allografts in only one form, which was a sheet form. In 2011, MiMedx introduced a micronized form of its sheet allografts.
	The U.S. Food and Drug Administration, or FDA, has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. If an HCT/P meets the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”), no FDA review for safety and effectiveness under a drug, device, or biological product marketing application is required. However, the processor of the tissue is required to register with the FDA, comply with regulations regarding labeling, record keeping, donor eligibility, and screening and testing, process the tissue in accordance with established Good Tissue Practices, and report any adverse events.
	To be a 361 HCT/P, a product generally must meet all four of the following criteria:
		·	It must be minimally manipulated;
		·	It must be intended for homologous use;
		·	Its manufacture does not involve combination with another article, except for water, crystalloids or a sterilizing, preserving or storage agent; and
		·	It does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function (unless the product is intended for reproductive use, autologous use, or use in a first or second degree blood relative).
	MiMedx believes that all of its tissue products qualify as 361 HCT/P’s, however, on August 28, 2013, the FDA issued an Untitled Letter alleging that the Company’s micronized allografts do not meet the minimal manipulation criteria for regulation solely under Section 361 of the Public Health Service Act due to the “micronization process which alters the original, relevant characteristics of the structural tissue, relating to the tissue’s utility for reconstruction, repair or replacement.” The Untitled Letter concluded that, as a result, MiMedx would need a biologics license to lawfully market the micronized products. Importantly, the Untitled Letter did not specify which relevant characteristics the FDA believes are altered by the micronization process.
	As explained on the FDA’s website, an “Untitled Letter is an initial correspondence with regulated industry that cites violations that do not meet the threshold of regulatory significance for a Warning Letter.” The Company was surprised by the Untitled Letter, considering the FDA conducted a directed inspection of our facility in July 2012, one of the express purposes of which was to determine the status of the Company’s AmnioFix® injectable product. The inspection report indicated that “information regarding the firms AmnioFix® Injectable product, which was rolled out August 2011, was collected and forwarded to CBER for review.  The information collected included advertising, packaging, process procedures and studies conducted related to the product.” Following that inspection, the inspector advised the Company that CBER had completed its review and had no findings or further questions and, therefore, the inspection was classified as NAI, or No Action Indicated. The formal establishment inspection report confirming the NAI conclusion was issued on December 4, 2012.
	On October 28, 2013, the Company met with the FDA to present the reasons it believes its micronized products do qualify as 361 HCT/Ps. The FDA acknowledged that our presentation included new information that they would review and consider, and they committed to responding in a timely fashion. We hope that, upon further analysis, the FDA will agree with our position. In all events, we are committed to continuing to work with the Agency to agree on a regulatory solution to ensure that our micronized products are available for patients who can benefit from their clinical effectiveness. If, ultimately, it is determined that our injectable products as currently marketed are not 361 HCT/Ps, in order to continue marketing our injectable products, we could have to do one or more of the following: change the labeling for the injectable products, modify the products or our processes, or go through the process of obtaining an approved biologics license for the injectable products. Any of the foregoing could create additional efforts and financial resources. If it is determined that we must obtain a biologics license for the injectable products, obtaining a biologics license requires substantial time, effort and financial resources and there is no assurance that any approvals for our injectable products will be granted on a timely basis, or at all. Further, unless we are permitted to continue to market our injectable products while we pursue a biologics license, we would have to discontinue marketing of those products. It is also possible that we would have to recall injectable products already on the market, though in light of the FDA’s actions in other situations with other HCT/P manufacturers, and the absence of any adverse reactions reported for our product, we consider the possibility of a recall to be remote and therefore not likely to have a material adverse impact on our financial position or results of operations.
	Litigation
	Following the publication of the Untitled Letter from the FDA regarding the Company’s injectable products in September 2013, four purported class action lawsuits were filed against us and certain of our executive officers. Two of the lawsuits were filed in the U.S. District Court for the Southern District of New York on September 9, 2013, and September 10, 2013, respectively. The other two lawsuits were filed in the U.S. District Court for the Northern District of Georgia on September 13, 2013, and September 19, 2013, respectively.
	Each complaint purports to be brought on behalf of shareholders who purchased our common stock during different time periods, beginning on various dates and all ending on September 4, 2013. The complaints generally allege that, during the differing class periods, all of the defendants violated Sections 10(b) of the Securities Exchange Act of 1934, or the Exchange Act, and SEC Rule 10b-5 and the individual defendants violated Section 20(a) of the Exchange Act in making various statements related to the Company’s belief that FDA approval was not required to market its products, including its micronized product. The complaints seek unspecified damages, interest, attorneys’ fees, and other costs. We and our executive officers intend to vigorously defend against these lawsuits. We currently believe that the outcome of this litigation will not have a material adverse impact on our financial position or results of operations.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
		Subsequent Events
	None.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Use of estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
	The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.  The Company has $115,000 and $49,000 in the allowance for doubtful accounts as of September 30, 2013, and December 31, 2012, respectively.  Actual customer collections could differ from estimates.  The approximate provision during the nine months ended September 30, 2013 and September 30, 2012, was $99,000 and 119,000, respectively, and there were approximately $33,000 and $23,000 of write-offs for the nine months ended September 30, 2013 and September 30, 2012, respectively.
Inventories	'
	Inventories
	Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
Revenue Recognition	'
	Revenue Recognition
	The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with the field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  The Company recorded approximately $178,000 and $88,000 for net sales returns provisions for the three months ended September 30, 2013 and 2012, respectively, and there were approximately $153,000 and $135,000 of charges against the related reserve during the three months ended September 30, 2013 and 2012, respectively. The Company recorded approximately $648,000 and $233,000 for net sales returns provisions for the nine months ended September 30, 2013 and 2012, respectively, and there were approximately $485,000 and $161,000 of charges against the related reserve during the nine months ended September 30, 2013 and 2012, respectively.
Patent Costs	'
	Patent Costs
	The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $527,000 of patent costs during the first nine months of 2013. There were not any patent costs capitalized for the nine months ended September 30, 2012.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The Company considers the applicability and impact of all ASUs. For the nine months ended September 30, 2013, and through the date of this report, all ASUs issued, effective and not yet effective, were assessed and determined to be either not applicable or are expected to have minimal impact on our financial position or results of operations.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventories consisted of the following items as of September 30, 2013, and December 31, 2012:
		September 30, 2013			December 31, 2012
	Raw materials	$	206,962		$	233,747
	Work in process	3,276,557			1,598,537
	Finished goods	1,422,275			1,349,121
		4,905,794			3,181,405
	Reserve for obsolescence	(372,732		)	(158,621		)
	Inventory, net	$	4,533,062		$	3,022,784

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and equipment consist of the following as of September 30, 2013, and December 31, 2012:
		30-Sep-13			31-Dec-12
	Leasehold improvements	$	2,638,508		$	1,022,230
	Lab and clean room equipment	2,265,203			1,887,645
	Furniture and office equipment	954,797			431,563
	Construction in progress	597,130			10,027
		6,455,638			3,351,465
	Less accumulated depreciation	(2,694,005		)	(2,279,840		)
		$	3,761,633		$	1,071,625

Intangible_Assets_and_Royalty_1

Intangible Assets and Royalty Agreement (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Activity	'
	Intangible assets activity is summarized as follows:
		30-Sep-13								31-Dec-12
		Weighted	Gross		Accumulated			Net		Gross		Impairment			Accumulated			Net
		Average	Carrying		Amortization			Carrying		Carrying		Adjustment			Amortization			Carrying
		Amortization	Value					Value		Value								Value
		Lives
	Intangible assets subject to amortization:
	License-Shriners Hsp for Children & USF Research (a)	10 years	$	996,000	$	(662,333	)	$	333,667	$	996,000	$	—		$	(587,633	)	$	408,367
	License - SaluMedica LLC Spine Repair (b)	10 years	1,547,324		(1,547,324		)	—		2,399,000		(851,676		)	(1,547,324		)	—
	License - Polyvinyl Alcohol Cryogel (c)	10 years	1,720,181		(1,319,956		)	400,225		2,667,000		(946,819		)	(1,223,561		)	496,620
	Customer Relationships (d)	14 years	3,520,000		(691,429		)	2,828,571		3,520,000		—			(502,857		)	3,017,143
	Supplier Relationships (d)	14 years	241,000		(47,339		)	193,661		241,000		—			(34,428		)	206,572
	Patents & Know-How (d)	17 years	5,614,177		(1,088,267		)	4,525,910		5,530,000		—			(790,000		)	4,740,000
	Micronized Processing Know-How (d)	14 years	2,160,000		(270,000		)	1,890,000		2,160,000		—			(154,286		)	2,005,714
	Licenses/Permits (d)	3 years	13,000		(11,917		)	1,083		13,000		—			(8,667		)	4,333
			15,811,682		(5,638,565		)	10,173,117		17,526,000		(1,798,495		)	(4,848,756		)	10,878,749
	Intangible assets not subject to amortization:
	Trade Names/Trademarks (d)	indefinite	1,008,000		—			1,008,000		1,008,000		—			—			1,008,000
	In-process Research & Development-Other (d)	indefinite	25,000		—			25,000		25,000		—			—			25,000
	Patents in Process (e)	indefinite	442,389					442,389		—		—			—			—
			$	16,844,682	$	(5,638,565	)	$	11,648,506	$	18,559,000	$	(1,798,495	)	$	(4,848,756	)	$	11,911,749
	(a)	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.  The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date).  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products.
	(b)	License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair.  This license was acquired through the acquisition of SpineMedica Corp.  In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value.
	(c)	On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol hydrogel.  The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date).  The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales.  On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement.  As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000.  In September 2012, the cost of the license was deemed to be impaired and reduced to its fair value.  At September 30, 2013, and December 31, 2012, there are no additional amounts accrued for this obligation due to its contingent nature.
	(d)	On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.
	(e)	Capitalized external legal and other registration costs in connection with internally developed tissue based patents that are pending issuance. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization
Estimated future amortization expense for intangible assets	'
	Expected future amortization of intangible assets is as follows:
		Estimated Amortization Expense
	Year ending  December 31,
	2013 (a)	$	263,833
	2014	1,050,998
	2015	1,028,944
	2016	981,950
	2017	891,753
	Thereafter	5,955,639
		$	10,173,117
	(a)	Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after September 30, 2013.

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Long-term Debt	'
	The following table summarizes our long-term debt:
		September 30,		December 31,
		2013		2012
	$5M Convertible Senior Secured Promissory Notes including interest at 5% per annum payable quarterly through December 31, 2013, and an additional one time 5% interest charge payable on January 15, 2013 if not repaid by December 31, 2012, collateralized by a first priority lien shared equally with holder of the Convertible Line of Credit with Related Party in all of the patents and intellectual property owned by the Company subordinated to the Convertible Debt related to acquisition for Surgical Biologics intellectual property until repaid. (a)	$	—	$	5,313,645
	Total debt	—		5,313,645
	Less unamortized debt discount	—		(1,301,203		)
	Less current portion	—		—
	Long-term portion	$	—	$	4,012,442
	(a) Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. On December 31, 2011, a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company's share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052, which was recorded as a debt discount and was amortized to interest expense using the effective interest rate over the life of the note.

Net_Income_loss_Per_Share_Tabl

Net Income (loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Net Loss per Share	'
	The following table sets forth the computation of basic and diluted net loss per share:
		Three months ended							Nine months ended
		September 30,							September 30,
		2013				2012			2013			2012
	Net income (loss)	$	(307,118	)		$	(4,219,372	)	$	(2,684,915	)	$	(6,057,092	)
	Denominator for basic earnings per share - weighted average shares	96,914,856				84,493,164			95,429,988			84,091,014
	Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	—				—			—			—
	Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	96,914,856				84,493,164			95,429,988			84,091,014
	Income (loss) per common share - basic and diluted	$	—			$	(0.05	)	$	(0.03	)	$	(0.07	)
	(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows
Summary of Antidilutive Securities	'
	(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:
		Nine months ended September 30,
		2013			2012
	Outstanding Stock Options	15,139,543			12,642,833
	Outstanding Warrants	1,923,669			3,241,668
	Convertible Debt, promissory notes	—			5,313,133
	Convertible Line of Credit with Related Party	—			1,391,524
		17,063,212			22,589,158

Equity_Tables

Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Stock Options Activity	'
	Activity with respect to the stock options is summarized as follows:
		Number of		Weighted-				Weighted-		Aggregate
		Shares		Average				Average		Intrinsic
				Exercise				Remaining		Value
				Price				Contractual
								Term
								(in years)
	Outstanding at January 1, 2013	13,614,135		$	1.42
	Granted	3,368,000		5.19
	Exercised	(1,610,426	)	0.94
	Unvested options forfeited	(179,167	)	3.82
	Vested options expired	(52,999	)	1.11
	Outstanding at September 30, 2013	15,139,543		2.28				7.9		$	31,918,608
	Vested at September 30, 2013	6,482,824		1.25				6.6		$	18,911,451
	Vested or expected to vest at September 30, 2013 (a)	14,824,937		$	2.25			7.9		$	31,649,823
	(a)	Includes forfeiture adjusted unvested shares.
Stock Options Outstanding and Exercisable	'
	Following is a summary of stock options outstanding and exercisable at September 30, 2013:
		Options Outstanding								Options Exercisable
	Range of Exercise Prices	Number outstanding		Weighted-		Weighted-				Number Exercisable		Weighted-
				Average		Average						Average
				Remaining		Exercise						Exercise Price
				Contractual		Price
				Term
				(in years)
	$0.50 - $0.76	1,340,935		3.9		$	0.65			1,340,935		$	0.65
	$0.87 - $1.35	6,656,908		7.9		1.2				3,336,870		1.19
	$1.40 - $2.29	1,686,700		6.4		1.62				1,436,698		1.65
	$2.33 - $3.75	2,159,500		9		2.75				368,321		2.52
	$3.95 - $6.02	3,035,000		9.5		5.07				—		—
	$6.11 - $6.75	260,500		9.7		6.49				—		—
		15,139,543		7.9		$	2.28			6,482,824		$	1.25
Fair Value of Options, Valuation Assumptions	'
	The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
		Nine months ended September 30,
		2013		2012
	Expected volatility	61.41 - 64.56%		45.75 - 64.3%
	Expected life (in years)	6		6
	Expected dividend yield	—		—
	Risk-free interest rate	0.85 -1.88%		0.62 - 1.62%
Allocation of Share-based Compensation	'
	For the three and nine months ended September 30, 2013 and 2012, the Company recognized stock-based compensation as follows:
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013			2012				2013			2012
	Cost of sales	$	75,287		$	11,643			$	198,119		$	65,132
	Research and development	110,694			70,754				309,461			217,885
	Selling, general and administrative	1,481,785			587,072				3,647,425			1,472,652
		$	1,667,766		$	669,469			$	4,155,005		$	1,755,669
Summary of Warrants Outstanding	'
	Following is a summary of the warrant activity for the nine months ended September 30, 2013:
		Number of		Weighted-
		Warrants		Average
				Exercise
				Price per
				Warrant
	Warrants outstanding at January 1, 2013	3,129,168		$	1.04
	Warrants exercised:
	Contingent warrants related to private placement of common stock	(62,500	)	0.01
	Callable warrants	(266,666	)	1.5
	Other	(876,333	)	1.23
	Warrants outstanding at September 30, 2013	1,923,669		$	0.93

Supplemental_disclosure_of_cas1

Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables)	9 Months Ended
	Sep. 30, 2013
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities	'
	Selected cash payments, receipts, and noncash activities are as follows:
		Nine Months Ended
		September 30,
		2013		2012
	Cash paid for interest	$	22,971	$	8,738
	Income taxes paid	96,967		—
	Purchases of property, plant and equipment financed capital leases	107,259		83,016
	Stock issuance of 167,086 shares in lieu of Director's fees	—		184,653
	Beneficial conversion related to line of credit with related party	—		514,456
	Stock issuance in connection with Earn-Out Liability of 1,174, 915 shares for 2013 and
	2,632,576 shares for 2012	5,792,330		3,185,223
	Stock issuance of 5,272,004 shares in exchange for convertible debt	5,272,004		—
	Company issued shares of 167,183 for cashless exercise	—		167
	Stock issuance of 893,267 shares in payment of Convertible Secured Promissory Notes	—		893,267
	related to acquisition of Surgical Biologics
	Tenant improvement incentive	996,866		—

Contractual_Commitments_Tables

Contractual Commitments (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Estimated Annual Lease, Royalty and Employment Agreement Expenses	'
	In addition to the Capital Leases noted under Property and Equipment above, the Company has entered into operating lease agreements for facility space and equipment.  The estimated annual lease payments are as follows:
	12-month period ended September 30
	2014	$	784,771
	2015	1,251,301
	2016	1,329,436
	2017	1,369,696
	2018	1,410,754
	Thereafter	478,326
		$	6,624,284

Basis_of_Presentation_Details

Basis of Presentation (Details)	9 Months Ended
	Sep. 30, 2013
	Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of business segments	1

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended			9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
						Patents [Member]	Patents [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'
Intangible assets, net of accumulated amortization	'	'	'	'	'	$527	$0
Accounts Receivable [Abstract]	'	'	'	'	'	'	'
Allowance for doubtful accounts	115	'	115	'	49	'	'
Provision for doubtful accounts	'	'	99	119	'	'	'
Accounts receivable charge-offs	'	'	33	23	'	'	'
Revenue Recognition [Abstract]	'	'	'	'	'	'	'
Net sales returns provision	178	88	648	233	'	'	'
Provision charges	$153	$135	$485	$161	'	'	'

Liquidity_and_Managements_Plan1

Liquidity and Management's Plans (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Liquidity and management's plans [Abstract]	'	'	'	'
Cash and cash equivalents	$6,061,756	$6,754,485	$7,621,226	$4,112,326
Total current assets	25,845,711	18,088,791	'	'
Total current liabilities	$8,331,394	$5,070,772	'	'

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]	'	'
Raw materials	$206,962	$233,747
Work in process	3,276,557	1,598,537
Finished goods	1,422,275	1,349,121
Gross Inventory	4,905,794	3,181,405
Reserve for obsolescence	-372,732	-158,621
Inventory, net	$4,533,062	$3,022,784

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property and equipment [Line Items]	'	'
Property and equipment, gross	$6,455,638	$3,351,465
Less accumulated depreciation	-2,694,005	-2,279,840
Property and equipment, net	3,761,633	1,071,625
Leasehold Improvements [Member]	'	'
Property and equipment [Line Items]	'	'
Property and equipment, gross	2,638,508	1,022,230
Lab and Clean Room Equipment [Member]	'	'
Property and equipment [Line Items]	'	'
Property and equipment, gross	2,265,203	1,887,645
Furniture and Office Equipment [Member]	'	'
Property and equipment [Line Items]	'	'
Property and equipment, gross	954,797	431,563
Construction in Progress [Member]	'	'
Property and equipment [Line Items]	'	'
Property and equipment, gross	597,130	10,027
Assets Held under Capital Leases [Member]	'	'
Property and equipment [Line Items]	'	'
Property and equipment, net	176,000	'
Leasehold Improvements Paid by Others [Member]	'	'
Property and equipment [Line Items]	'	'
Property and equipment, net	$1,000,000	'

Intangible_Assets_and_Royalty_2

Intangible Assets and Royalty Agreement (Details) (USD $)

0 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

Mar. 31, 2008

Jan. 29, 2007

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Trade Names and Trademarks [Member]

Trade Names and Trademarks [Member]

In Process Research and Development, Other [Member]

In Process Research and Development, Other [Member]

Patents in Process [Member]

Patents in Process [Member]

License-Shriners Hsp for Children & USF Research [Member]

License-Shriners Hsp for Children & USF Research [Member]

License - SaluMedica LLC Spine Repair [Member]

License - SaluMedica LLC Spine Repair [Member]

License - Polyvinyl Alcohol Cryogel [Member]

License - Polyvinyl Alcohol Cryogel [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Supplier Relationships [Member]

Supplier Relationships [Member]

Patents and Know-How [Member]

Patents and Know-How [Member]

Micronized Processing Know-How [Member]

Micronized Processing Know-How [Member]

Licenses and Permits [Member]

Licenses and Permits [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Amortization Lives

'

'

'

'

'

'

'

'

'

'

'10 years

[1]

'

'10 years

[2]

'

'10 years

[3]

'

'14 years

[4]

'

'14 years

[4]

'

'17 years

[4]

'

'14 years

[4]

'

'3 years

[4]

'

Gross Carrying Value

'

'

$15,811,682

$17,526,000

'

'

'

'

'

'

$996,000

[1]

$996,000

[1]

$1,547,324

[2]

$2,399,000

[2]

$1,720,181

[3]

$2,667,000

[3]

$3,520,000

[4]

$3,520,000

[4]

$241,000

[4]

$241,000

[4]

$5,614,177

[4]

$5,530,000

[4]

$2,160,000

[4]

$2,160,000

[4]

$13,000

[4]

$13,000

[4]

Accumulated Amortization

'

'

-5,638,565

-4,848,756

'

'

'

'

'

'

-662,333

[1]

-587,633

[1]

-1,547,324

[2]

-1,547,324

[2]

-1,319,956

[3]

-1,223,561

[3]

-691,429

[4]

-502,857

[4]

-47,339

[4]

-34,428

[4]

-1,088,267

[4]

-790,000

[4]

-270,000

[4]

-154,286

[4]

-11,917

[4]

-8,667

[4]

Acquisition price, one-time license fee

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment Adjustment

'

'

'

-1,798,495

'

'

'

'

'

'

'

'

'

-851,676

[2]

'

-946,819

[3]

'

'

'

'

'

'

'

'

'

'

Net carrying value, Total

'

'

10,173,117

10,878,749

'

'

'

'

'

'

333,667

[1]

408,367

[1]

0

[2]

0

[2]

400,225

[3]

496,620

[3]

2,828,571

[4]

3,017,143

[4]

193,661

[4]

206,572

[4]

4,525,910

[4]

4,740,000

[4]

1,890,000

[4]

2,005,714

[4]

1,083

[4]

4,333

[4]

Shares issued for intangibles (in shares)

'

1,120,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of shares issued for intangibles

'

896,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum time of approval

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent payments to licensor

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent royalty to be paid to licensor (in hundredths)

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition price of asset, shares issued (in shares)

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition of asset, value of shares issued

2,596,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issuable upon meeting certain milestones (in shares)

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent payments to licensor, shares issued (in shares)

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent payment to licensor, value of shares issued

71,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional accrued obligation

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite-lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average useful life Indefinite lived

'

'

'

'

'indefinite

[4]

'

'indefinite

[4]

'

'indefinite

[5]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Value

'

'

'

'

1,008,000

[4]

1,008,000

[4]

25,000

[4]

25,000

[4]

442,389

[5]

0

[5]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated Amortization

'

'

'

'

0

[4]

0

[4]

0

[4]

0

[4]

'

0

[5]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Carrying Value

'

'

'

'

1,008,000

[4]

1,008,000

[4]

25,000

[4]

25,000

[4]

442,389

[5]

0

[5]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets, gross carrying value

'

'

16,844,682

18,559,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment Adjustment

'

'

'

-1,798,495

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated Amortization

'

'

-5,638,565

-4,848,756

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets, net carrying value

'

'

11,648,506

11,911,749

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated future amortization expense [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2013

'

'

263,833

[6]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

'

'

1,050,998

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

'

'

1,028,944

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

'

'

981,950

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

'

'

891,753

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Thereafter

'

'

$5,955,639

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date). Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products

[2]

License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value

[3]

On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol hydrogel. The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date). The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales. On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement. As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000. In September 2012, the cost of the license was deemed to be impaired and reduced to its fair value. At September 30, 2013, and December 31, 2012, there are no additional amounts accrued for this obligation due to its contingent nature

[4]

On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development

[5]

Capitalized external legal and other registration costs in connection with internally developed tissue based patents that are pending issuance. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization

[6]

)Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after September 30, 2013.

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)

0 Months Ended

3 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

2 Months Ended

9 Months Ended

Jan. 29, 2007

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2011

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2011

Jul. 03, 2012

Jul. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2011

Feb. 28, 2013

Sep. 30, 2013

17-May-13

17-May-13

17-May-13

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

5% Convertible Senior Secured Promissory Note [Member]

Loan Agreement [Member]

Loan Agreement [Member]

Revolving Credit Facility [Member]

Letter of Credit [Member]

London Interbank Offered Rate (LIBOR) [Member]

First Contingent Warrants [Member]

First Contingent Warrants [Member]

Second Contingent Warrants [Member]

Second Contingent Warrants [Member]

Second Contingent Warrants [Member]

Second Contingent Warrants [Member]

Chairman and CEO [Member]

Loan Agreement [Member]

Loan Agreement [Member]

Loan Agreement [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total debt

'

$0

$5,313,645

$0

[1]

$0

[1]

'

$5,313,645

[1]

'

'

'

'

'

'

'

'

'

'

'

'

Less unamortized debt discount

'

0

1,301,203

'

'

'

'

'

'

'

'

'

'

'

'

1,328,000

'

'

'

Less current portion

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term portion

'

0

4,012,442

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual interest rate (in hundredths)

'

5.00%

'

5.00%

5.00%

5.00%

5.00%

'

'

'

'

'

'

'

'

'

'

'

2.00%

Maturity date

'

'

'

'

31-Dec-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional interest payment (in hundredths)

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of equity securities to be sold for conversion of notes (in hundredths)

'

'

'

'

'

'

'

25.00%

'

'

'

25.00%

'

'

'

'

'

'

'

Warrant exercise price (in dollars per share)

'

'

'

'

$1.09

'

'

$0.01

'

'

'

'

$0.01

'

'

'

'

'

'

Warrants vested (in shares)

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

'

'

'

Warrants voided (in shares)

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

'

Closing trading price of Company stock (in dollars per share)

'

'

'

'

'

'

'

'

'

$1.75

'

'

'

'

'

'

'

'

'

Number of consecutive trading days

'

'

'

'

'

'

'

'

'

'

'10 days

'

'

'

'

'

'

'

'

Beneficial Conversion Feature Value Related To Convertible Debt Issued With Regard To Senior Secured Promissory Notes

'

'

'

'

'

'

'

2,278,052

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of debt

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

500,000

'

'

'

'

'

Convertible debt, shares issuable if converted (in shares)

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Unpaid interest to be considered for conversion in to shares of common stock (in dollars per share)

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

Placement fee

'

'

'

32,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Placement fee, warrants issued (in shares)

1,120,000

'

'

42,400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants term

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of placement fee warrants

'

'

'

15,000

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Direct costs of sale of notes

'

'

'

47,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,272,000

'

'

'

'

Convertible secured promissory note to common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,272,000

532,260

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,000,000

$1,000,000

'

[1]

Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. On December 31, 2011, a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company's share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052, which was recorded as a debt discount and was amortized to interest expense using the effective interest rate over the life of the note.

Net_Income_loss_Per_Share_Deta

Net Income (loss) Per Share (Details) (USD $)	3 Months Ended				9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Computation of basic and diluted net loss per share [Abstract]	'		'		'		'
Net income (loss)	($307,118)		($4,219,372)		($2,684,915)		($6,057,092)
Denominator for basic earnings per share - weighted average shares (in shares)	96,914,856		84,493,164		95,429,988		84,091,014
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares)	0	[1]	0	[1]	0	[1]	0	[1]
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares)	96,914,856		84,493,164		95,429,988		84,091,014
Income (loss) per common share - basic and diluted (in dollars per share)	$0		($0.05)		($0.03)		($0.07)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	'		'		17,063,212		22,589,158
Outstanding Stock Options [Member]	'		'		'		'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	'		'		15,139,543		12,642,833
Outstanding Warrants [Member]	'		'		'		'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	'		'		1,923,669		3,241,668
Convertible Debt, Promissory Notes [Member]	'		'		'		'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	'		'		0		5,313,133
Revolving Credit Facility [Member]	'		'		'		'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	'		'		0		1,391,524
[1]	Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:

Equity_Details

Equity (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Plan

Warrants [Member]

Warrants [Member]

Contingent Warrants Related to Private Placement of Common Stock [Member]

Callable Warrants [Member]

Other [Member]

Cost of Products Sold [Member]

Cost of Products Sold [Member]

Cost of Products Sold [Member]

Cost of Products Sold [Member]

Research and Development [Member]

Research and Development [Member]

Research and Development [Member]

Research and Development [Member]

Selling, General and Administrative [Member]

Selling, General and Administrative [Member]

Selling, General and Administrative [Member]

Selling, General and Administrative [Member]

$0.50-$0.76 [Member]

$0.87-$1.35 [Member]

$1.40-$2.29 [Member]

$2.33-$3.75 [Member]

$3.95-$6.53 [Member]

$6.60-$6.75 [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Stock Options [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Warrants [Member]

Warrants [Member]

Warrants [Member]

Maximum [Member]

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of share-based compensation plans

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding assumed options (in shares)

375,000

'

375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional shares authorized by Board of Directors (in shares)

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized (in shares)

22,500,000

'

22,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expenses expected to be recognized over a weighted-average period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 2 months 24 days

'2 years 6 months

'

'

Number of shares granted (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

419,300

'

'

Weighted-average grant date fair value (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.58

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'1 year

Total unrecognized stock-based compensation related to time-based, nonvested restricted stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,894,000

'

'

Total unrecognized compensation expense

11,438,000

'

11,438,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares [Roll forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, beginning of period (in shares)

'

'

13,614,135

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

3,368,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in shares)

'

'

-1,610,426

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested options forfeited (in shares)

'

'

-179,167

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested options expired (in shares)

'

'

-52,999

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, end of period (in shares)

15,139,543

'

15,139,543

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested at end of period (in shares)

6,482,824

'

6,482,824

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable options, vested and expected to vest (in shares)

14,824,937

'

14,824,937

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-Average Exercise Price [Roll forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, weighted average exercise price, beginning of period (in dollars per share)

'

'

$1.42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted, weighted average exercise price (in dollars per share)

'

'

$5.19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised, weighted average exercise price (in dollars per share)

'

'

$0.94

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested options forfeited weighted-average exercise price (in dollars per share)

'

'

$3.82

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested options expired weighted-average exercise price (in dollars per share)

'

'

$1.11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, weighted average exercise price, end of period (in dollars per share)

$2.28

'

$2.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested at end of period weighted average exercise price (in dollars per share)

$1.25

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest, weighted average exercise price (in dollars per share)

$2.25

'

$2.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options, additional disclosures [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested at end of period weighted average remaining contractual term

'

'

'6 years 7 months 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest, weighted average remaining contractual term

'

'

'7 years 10 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding intrinsic value

31,918,608

'

31,918,608

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested at end of period aggregate intrinsic value

18,911,451

'

18,911,451

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest, aggregate intrinsic value

31,649,823

'

31,649,823

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised options, intrinsic value

7,182,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price Range, lower range limit (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.50

$0.87

$1.40

$2.33

$3.95

$6.11

'

'

'

'

'

'

'

'

Exercise Price Range, upper range limit (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.76

$1.35

$2.29

$3.75

$6.02

$6.75

'

'

'

'

'

'

'

'

Number of outstanding options (in shares)

15,139,543

'

15,139,543

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,340,935

6,656,908

1,686,700

2,159,500

3,035,000

260,500

'

'

'

'

'

'

'

'

Outstanding Options, weighted average remaining contractual term

'7 years 10 months 24 days

'

'7 years 10 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 10 months 24 days

'7 years 10 months 24 days

'6 years 4 months 24 days

'9 years

'9 years 6 months

'9 years 8 months 12 days

'

'

'

'

'

'

'

'

Outstanding Options, weighted average exercise price (in dollars per share)

$2.28

'

$2.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.65

$1.20

$1.62

$2.75

$5.07

$6.49

'

'

'

'

'

'

'

'

Number of exercisable options (in shares)

6,482,824

'

6,482,824

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,340,935

3,336,870

1,436,698

368,321

0

0

'

'

'

'

'

'

'

'

Exercisable Options, weighted average exercise price (in dollars per share)

$1.25

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.65

$1.19

$1.65

$2.52

$0

$0

'

'

'

'

'

'

'

'

Fair value options valuation assumptions [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64.56%

64.30%

61.41%

45.75%

'

'

'

'

Expected life

'

'

'

'6 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years

'

'5 years 6 months

'

'

'

'

'

Expected dividend yield (in hundredths)

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate, minimum (in hundredths)

'

'

0.85%

0.62%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate, maximum (in hundredths)

'

'

1.88%

1.62%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

$1,667,766

$669,469

$4,155,005

$1,755,669

'

'

'

'

'

$75,287

$11,643

$198,119

$65,132

$110,694

$70,754

$309,461

$217,885

$1,481,785

$587,072

$3,647,425

$1,472,652

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average grant date fair value for options granted during the period (in dollars per share)

$3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, term

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, Number of Warrants [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding, beginning of period (in shares)

'

'

'

'

1,923,669

3,129,168

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised (in shares)

'

'

'

'

'

'

-62,500

-266,666

-876,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding, end of period (in shares)

'

'

'

'

1,923,669

3,129,168

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding, beginning of period (in dollars per share)

'

'

'

'

0.93

1.04

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised (in dollars per share)

'

'

'

'

'

'

0.01

1.5

1.23

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding, end of period (in dollars per share)

'

'

'

'

0.93

1.04

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_taxes_Details

Income taxes (Details) (USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
Research Tax Credit [Member]	'
Tax Credit Carryforward [Line Items]	'
Tax credit carryforwards	$1.40
Internal Revenue Service (IRS) [Member]	'
Operating Loss Carryforwards [Line Items]	'
Operating loss carryforwards	$43.40

Supplemental_disclosure_of_cas2

Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]	'	'
Cash paid for interest	$22,971	$8,738
Income taxes paid	96,967	0
Purchases of property, plant and equipment financed via capital leases	107,259	83,016
Stock issuance of 167,086 shares in lieu of Director's fees	0	184,653
Stock Issuance in lieu of Director's fees (in shares)	'	167,086
Beneficial conversion related to line of credit with related party	0	514,456
Stock issuance in connection with Earn-Out Liability of 1,174, 915 shares for 2013 and 2,632,576 shares in 2012	5,792,330	3,185,223
Stock issued for earn-out liability (in shares)	1,174,915	2,632,576
Stock issuance in exchange for convertible debt	5,272,004	0
Stock issued for convertible debt (in shares)	5,272,004	'
Cashless exercise of warrants	0	167
Stock issuance of 893,267 shares in payment of Convertible Secured Promissory Notes related to acquisition of Surgical Biologics	0	893,267
Stock issued related to acquisition of Surgical Biologics (in shares)	'	893,267
Shares issued for Cashless Exercise (in shares)	'	167,183
Tenant improvement incentive	$996,866	$0

Contractual_Commitments_Detail

Contractual Commitments (Details) (USD $)	Sep. 30, 2013
Estimated annual lease, royalty, and employment agreement expenses [Abstract]	'
2014	$784,771
2015	1,251,301
2016	1,329,436
2017	1,369,696
2018	1,410,754
Thereafter	478,326
Total Contractual commitments	6,624,284
Standby Letters of Credit [Member]	'
Loss Contingencies [Line Items]	'
Standby letters of credit	$525,000